SCHEMBL1615984

SCHEMBL1615984

COC(=O)c1ncc(Cl)nc1Nc1ccc([Si](C)(C)C)cc1F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 1/20 0.36
▸ ALK Q9UM73 2/20 0.36
▸ THRB P10828 1/20 0.36
▸ DHODH Q02127 2/20 0.35
▸ FGFR1 P11362 1/20 0.34
▸ FLT1 P17948 1/20 0.34
▸ EPHB2 P29323 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ NUDT1 P36639 5/20 0.34
▸ CSF1R P07333 1/20 0.34
▸ MAPK14 Q16539 2/20 0.34
▸ MAP2K1 Q02750 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ DYRK1B Q9Y463 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPK3 P27361 1/20 0.32
▸ MAPK9 P45984 1/20 0.32
▸ MAPK10 P53779 1/20 0.32
▸ MAPK13 O15264 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1615191 0.89 AURKA (0.36) EGFRALKTHRBDHODHNUDT1
SCHEMBL1615058 0.86 APP (0.34) EGFRALKTHRBDHODHMAPK14
SCHEMBL1615631 0.84 THRB (0.36) EGFRALKTHRBDHODHNUDT1
SCHEMBL31135611 0.82 TUBB4A (0.38) EGFRALKTHRBDHODHFGFR1
SCHEMBL1615868 0.82 TUBB4A (0.38) EGFRALKTHRBDHODHFGFR1
SCHEMBL1615831 0.81 THRB (0.35) ALKTHRBDHODHMAPK14MAPK13
SCHEMBL1615894 0.77 KEAP1 (0.37) EGFRALKTHRBDHODHFGFR1
SCHEMBL31135656 0.77 KEAP1 (0.37) EGFRALKTHRBDHODHFGFR1
SCHEMBL31135609 0.74 DHODH (0.41) DHODHNUDT1MAP2K1
SCHEMBL1615111 0.74 DHODH (0.41) DHODHNUDT1MAP2K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206174-B2 5-anilinoimidazopyridines and methods of use GENENTECH, INC. (US) 2015-12-08 — — US disclosed
US-9206174-B2 5-anilinoimidazopyridines and methods of use GENENTECH, INC. (US) 2015-12-08 — — US disclosed
EP-2690101-B1 5-Anilinoimidazopyridines and Methods of Use GENENTECH INC (US) 2015-06-24 — — EP disclosed
EP-2690101-A1 5-Anilinoimidazopyridines and Methods of Use Genentech, Inc. (US) 2014-01-29 — — EP disclosed
EP-2222675-B1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH INC (US) 2013-09-11 — — EP disclosed
EP-2222675-B1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH INC (US) 2013-09-11 — — EP disclosed
US-20130150584-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2013-06-13 — — US disclosed
US-20130150584-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2013-06-13 — — US disclosed
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2012-12-06 — — US disclosed
US-8288408-B2 5-anilinoimidazopyridines and methods of use GENENTECH, INC. (US) 2012-10-16 — — US disclosed
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2011-06-30 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
US-7923456-B2 5-anilinoimidazo[1,5-a]-pyridines inhibitors of MEK kinase GENENTECH, INC. (US) 2011-04-12 — — US disclosed
EP-2222675-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE Genentech, Inc. (US) 2010-09-01 — — EP disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2010-01-07 — — US disclosed
WO-2009085983-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE GENENTECH, INC. (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309765-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP EGFR 996/4885ALK 1819/4885THRB 3487/4885
US-20110158990-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP EGFR 996/4885ALK 1819/4885THRB 3487/4885
US-20100004269-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, MAP3K5, MAPKAPK5 EGFR 333/4885ALK 575/4885THRB 3971/4885
US-20130150584-A1 5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE MKI67, PCNA, TYMP EGFR 996/4885ALK 1819/4885THRB 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback